Skip to main content
. 2017 Sep 1;7(9):1835–1849.

Figure 3.

Figure 3

AKT2 mRNA is a direct target of miR-625, and AKT2 protein expression is inversely correlated with that of miR-625 in glioma tissues. (A) Predicted miR-625 target sequence in the wild-type (WT) 3’-UTR of AKT2 mRNA and the mutated construct (mut). (B) Levels of miR-625 in U87 and U251 cells after ectopic expression of miR-625 or miR-NC. (C) Luciferase reporter assay of U87 and U251 cells co-transfected with miR-625 mimic and either pmiRNA-AKT2/3’-UTR-WT or pmiRNA-AKT2/3’-UTR-Mut. (D) Western blot analysis of AKT2 protein expression levels in U87 and U251 cells transfected with miR-NC or miR-625. GAPDH served as the loading control. (E, F) Analysis of AKT2 expression in glioblastoma multiforme (GBM) and normal brain tissue (NBT) from the TCGA (E) and GSE16011 (F) datasets. (G) Western blot analysis of AKT2 protein expression in normal human astrocytes (NHAs) and U87, LN229, U251, A172, and U118 glioma cell lines. (H) Western blot analysis of AKT2 protein expression in five NBTs and 26 glioma specimens. Expression levels were normalized to GAPDH levels. P = 0.0033. (I) Spearman’s correlation analysis of AKT2 protein and miR-625 expression levels in human glioma specimens (r = −0.6035, P < 0.001). **P < 0.01.